In short
Tirzepatide (Eli Lilly, LY3298176) is a dual hormone receptor agonist that activates the GIP and GLP-1 receptors at once. In the SURMOUNT-1 trial it reached a mean weight reduction of 20.9% over 72 weeks (Jastreboff et al., NEJM 2022), and in the SURPASS-2 head to head it outperformed semaglutide on HbA1c and body weight (Frías et al., NEJM 2021). The molecule is approved in human medicine under the brand names Mounjaro and Zepbound; the research grade material discussed here is a separate category supplied strictly as research use only (RUO).
What is tirzepatide?
Tirzepatide is a synthetic 39 amino acid acylated peptide that simultaneously activates two incretin receptors, GIP and GLP-1, making it the first dual agonist of its class to complete a full clinical programme. Its molecular mass is 4,813.5 Da and a C20 fatty diacid attached via a lysine residue binds it to albumin in the blood, extending the half life to roughly five days and supporting once weekly administration in trials.
Where semaglutide targets the GLP-1 receptor alone, tirzepatide adds GIP receptor activation, and that second pathway is the reason it became the reference point of the field until triple agonists arrived. Full technical specifications, batch documentation and the certificate of analysis are on the tirzepatide research peptide page.
How does tirzepatide work?
Tirzepatide is a dual agonist: it activates the GIP receptor and the GLP-1 receptor together (Coskun et al., Mol Metab 2018, PubMed 30473097). The GLP-1 component slows gastric emptying and acts centrally in the hypothalamus and area postrema to suppress appetite, while GIP receptor activation contributes to the regulation of food intake and insulin response and is associated in research with a reduction of nausea. The combined signal of both receptors is the working explanation for why the dual agonist outperformed GLP-1 mono agonism in trials.
The next step of the same logic adds a third receptor: retatrutide pairs GIP and GLP-1 with glucagon receptor activation, and the two molecules are compared in detail in the retatrutide vs tirzepatide article.
Tirzepatide trial results
In SURMOUNT-1 (Jastreboff et al., NEJM 2022, PubMed 35658024), tirzepatide 15 mg once weekly produced a mean weight reduction of 20.9% over 72 weeks in 2,539 participants, at the time the strongest result published for an incretin based molecule. The result moved the bar set by semaglutide (14.9% in STEP-1) and established dual agonism as superior to mono agonism in weight reduction.
The programme extended beyond weight. In diabetes, the SURPASS trials showed strong HbA1c reductions, and SURMOUNT-OSA (Malhotra et al., NEJM 2024) demonstrated a significant reduction in obstructive sleep apnea severity, the first evidence that an incretin molecule can directly affect this comorbidity. The SYNERGY-NASH programme reported liver fat reductions in the range of 50 to 60%. These are trial outcomes in patient populations, not guaranteed or transferable results.
Tirzepatide vs semaglutide
Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide activates GLP-1 alone. In the only direct head to head, SURPASS-2 (Frías et al., NEJM 2021, PubMed 34170647), tirzepatide was superior to semaglutide 1 mg on both HbA1c (2.30% vs 1.86% reduction) and body weight in patients with type 2 diabetes. In separate obesity programmes, tirzepatide reached 20.9% in SURMOUNT-1 against 14.9% for semaglutide in STEP-1 (Wilding et al., NEJM 2021, PubMed 33567185); those two figures come from different trials with different populations, so the comparison is indicative rather than direct.
| Criterion | Tirzepatide | Semaglutide |
|---|---|---|
| Receptors | GIP + GLP-1 | GLP-1 |
| Head to head (SURPASS-2, HbA1c) | −2.30% | −1.86% |
| Obesity trial weight reduction | 20.9% (SURMOUNT-1, 72 wks) | 14.9% (STEP-1, 68 wks) |
| Half-life | ~5 days | ~7 days |
| Approval status | approved (Mounjaro/Zepbound) | approved (Ozempic/Wegovy) |
The broader ranking of metabolic peptides by trial data is in the peptides and weight research overview.
Molecular stability and handling in the laboratory
Tirzepatide is a 39 amino acid peptide with a C20 fatty diacid chain that binds albumin, which is why its plasma half life in published pharmacokinetic work is around 5 days. For laboratory work the practical consequence is different from the clinical one: the same acylation that slows clearance in vivo also makes the lyophilized material comparatively robust, provided it is stored at 2 to 8 degrees Celsius, protected from light and reconstituted only immediately before an experiment. In aqueous solution peptides of this class degrade over days to weeks, the lyophilizate stays stable for years.
How batch quality is verified
Every Molequa® batch is analysed by the independent laboratory Janoshik Analytical. The batch certificate states HPLC purity and confirms identity by mass spectrometry, and it is available on the product page before purchase rather than after.
An in-house analysis by the seller and an analysis by an independent laboratory are not the same evidence. A purity figure with no chromatogram attached is a claim, not proof.
Legal status and where tirzepatide fits
Tirzepatide is an approved molecule in human medicine: the brand names Mounjaro (type 2 diabetes, 2022) and Zepbound (obesity, 2023) contain it as the active ingredient and are dispensed on prescription. Research grade tirzepatide is a different category entirely: at Molequa® it is available strictly for laboratory research, supplied as research use only (RUO) material with HPLC/MS testing and per batch documentation on the tirzepatide product page. It is not a medicine and must not be used as one, and the brand names are mentioned solely for molecule recognition.
FAQ
What is tirzepatide? A synthetic 39 amino acid dual GIP/GLP-1 receptor agonist developed by Eli Lilly (LY3298176), studied for metabolic parameters and approved in human medicine under the names Mounjaro and Zepbound.
How strong is tirzepatide in trials? SURMOUNT-1 reported a mean weight reduction of 20.9% over 72 weeks at 15 mg once weekly (Jastreboff et al., NEJM 2022).
How is tirzepatide different from semaglutide? Tirzepatide adds GIP receptor activation to the GLP-1 mechanism. In the SURPASS-2 head to head it was superior to semaglutide 1 mg on HbA1c and body weight.
How is tirzepatide different from retatrutide? Retatrutide adds a third receptor (glucagon) and reached 24.2% in Phase 2 (Jastreboff et al., NEJM 2023, PubMed 37366315), but remains investigational while tirzepatide is approved. See the full comparison.
Where can I get tirzepatide for research? Molequa® supplies research grade tirzepatide as an RUO reference material with independent HPLC/MS testing and EU shipping; availability is shown on the product page.
Legal notice: Research tirzepatide is offered exclusively for scientific laboratory research (RUO). It is not intended for human or animal consumption and it is not the approved medicine sold under the brand names Mounjaro or Zepbound, which are listed only for molecule recognition. This article summarises published research data and is not medical advice.
